- The Company's audited Annual Report 2014.
- The remuneration of the Board of Directors for 2014 and the level for 2015.
- Distribution of profit according to the adopted Annual Report 2014. The dividend will be DKK 5.00 per A and B share of DKK 0.20.
- Re-election of Göran Ando as chairman and Jeppe Christiansen as vice chairman of the Board of Directors.
- Re-election of Bruno Angelici, Liz Hewitt, and Thomas Paul Koestler as members of the Board of Directors.
- Election of Sylvie Grégoire, Eivind Kolding and Mary Szela as new members of the Board of Directors.
- Re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as the Company's auditor.
- Reduction of the Company's B share capital by cancellation of part of the Company's own holding of B shares. The Company's B shares are reduced by DKK 10,000,000 from DKK 422,512,800 to DKK 412,512,800.
- Authorisation to the Board of Directors until the next Annual General Meeting to allow the Company to repurchase own shares of up to 10% of the share capital subject to a holding limit of 10% of the share capital.
- Amendment to the Articles of Association to allow distribution of extraordinary dividend.
- Revised Remuneration Principles.
Further information
Media: | ||
Mike Rulis | +45 3079 3573 | mike@novonordisk.com: mailto:mike@novonordisk.com |
Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com: mailto:kiau@novonordisk.com |
Investors: | ||
Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com: mailto:krop@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com: mailto:dabo@novonordisk.com |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com: mailto:mrz@novonordisk.com |
Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com: mailto:fdni@novonordisk.com |
http://hugin.info/2013/R/1904763/677683.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire